Terminated PHASE1 INTERVENTIONAL 2-arm NCT05609942

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies (AZURE)

A Phase 1/2, Open-label, 2-arm Study Evaluating BLU-263 as Monotherapy and in Combination With Azacitidine, in Patients With KIT Altered Hematologic Malignancies

Sponsor: Blueprint Medicines Corporation

Conditions Advanced Systemic Mastocytosis

Interventions Azacitidine BLU-263

Updated 9 times since 2022 Last updated: Apr 8, 2025 Started: Sep 25, 2023 Primary completion: Jan 14, 2025 Completion: Mar 10, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Terminated - alignment of strategic priorities

Other terminated trials from Blueprint Medicines Corporation

More terminations from Blueprint Medicines Corporation

Listed as NCT05609942, this PHASE1 trial focuses on Advanced Systemic Mastocytosis and remains terminated or withdrawn. Sponsored by Blueprint Medicines Corporation, it has been updated 9 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

May 2025 — Present [monthly]

Terminated PHASE1

Status: Active Not Recruiting → Terminated
Mar 2025 — May 2025 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting · Phase: PHASE1/PHASE2 → PHASE1
Sep 2024 — Mar 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 4 earlier versions

Mar 2024 — May 2024 [monthly]

Recruiting PHASE1_PHASE2
Nov 2023 — Mar 2024 [monthly]

Recruiting PHASE1_PHASE2
May 2023 — Nov 2023 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Dec 2022 — May 2023 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Blueprint Medicines Corporation

Data source: Blueprint Medicines Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Boston, United States , Caen, France , Edegem, Belgium , Ghent, Belgium , Maastricht, Netherlands , Mannheim, Germany , Oslo, Norway , Palo Alto, United States , Salt Lake City, United States and 1 more location